Medicare Enrolled

Dr. Atul Singhal, M.D. FACR

Rheumatology · Mesquite, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
1600 REPUBLIC PKWY, Mesquite, TX 75150
9722882600
Registered in NPPES since 2006
NPI: 1346256773 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Singhal from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Singhal? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Singhal

Dr. Atul Singhal is a rheumatology specialist in Mesquite, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Singhal performed 64,440 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Singhal received a total of $39,065 from 39 pharmaceutical and/or device companies across 997 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Singhal is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration ▲ Top 19% volume in TX $39,065 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
64,440
Medicare services
Top 19% in TX for rheumatology
Not available
Unique patients (not deduplicated)
$4
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
63,600 $4 $13
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
262 $57 $190
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
184 $96 $345
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
104 $22 $110
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
83 $92 $270
Steroid injection (triamcinolone)
A 10 mg injection of triamcinolone acetonide, a corticosteroid medication. This code specifies the drug and dosage administered.
73 $1 $15
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
54 $66 $184
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
49 $12 $69
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
31 $52 $270
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
0.3% high complexity
99.5% medium
0.2% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$39,065
Total received (2018-2024)
Avg $5,581/year across 7 years
Top 12% in TX for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
39
Companies
997
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,661
2023
$2,362
2022
$2,967
2021
$2,740
2020
$6,227
2019
$10,420
2018
$10,688

Payments by company (2024)

UCB SA
$1,159
ABBVIE INC.
$576
Novartis Pharmaceuticals Corporation
$500
Amgen Inc.
$256
UCB, Inc.
$223
GlaxoSmithKline, LLC.
$193
Janssen Scientific Affairs, LLC
$142
AstraZeneca Pharmaceuticals LP
$122
Celgene Corporation
$104
Janssen Biotech, Inc.
$88
Radius Health, Inc.
$80
PFIZER INC.
$66
Organon Llc
$65
Fresenius Kabi USA, LLC
$50
Octapharma USA, Inc.
$23
Lilly USA, LLC
$15
Top 3 companies account for 61.0% of 2024 payments
All-time payments by company (2018-2024) ›
AbbVie, Inc.
$11,122
AbbVie Inc.
$6,136
Horizon Therapeutics plc
$3,455
Novartis Pharmaceuticals Corporation
$2,251
ABBVIE INC.
$1,797
CSL Behring
$1,776
UCB Biosciences Inc.
$1,721
Amgen Inc.
$1,676
UCB, Inc.
$1,449
UCB SA
$1,159
Janssen Biotech, Inc.
$877
Genentech USA, Inc.
$844
GlaxoSmithKline, LLC.
$712
AstraZeneca Pharmaceuticals LP
$561
E.R. Squibb & Sons, L.L.C.
$499
GENZYME CORPORATION
$475
PFIZER INC.
$357
Mallinckrodt Hospital Products Inc.
$331
Lilly USA, LLC
$302
Organon LLC
$229
Aurinia Pharma U.S., Inc.
$226
Celgene Corporation
$206
Janssen Scientific Affairs, LLC
$142
Boehringer Ingelheim Pharmaceuticals, Inc.
$140
Radius Health, Inc.
$128
Alexion Pharmaceuticals, Inc.
$89
Fresenius Kabi USA, LLC
$65
Organon Llc
$65
Horizon Pharma plc
$61
BOSTON SCIENTIFIC CORPORATION
$39
Antares Pharma, Inc.
$31
Gilead Sciences, Inc.
$28
Octapharma USA, Inc.
$23
SOBI, INC
$21
Teva Pharmaceuticals USA, Inc.
$18
Medtronic, Inc.
$16
Sandoz Inc.
$14
Merck Sharp & Dohme Corporation
$12
MEDAC PHARMA, INC.
$12
Top 3 companies account for 53.0% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AMJEVITA · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · DUEXIS · EVENITY · Enbrel · FORTEO · GENERAL THERAPIES · HADLIMA · HUMIRA · HYRIMOZ · Hizentra · Humira · IDACIO · INFLECTRA · INTELLIS ADAPTIVESTIM · KEVZARA · KINERET · KRYSTEXXA · LUPKYNIS · NEXPLANON · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · Otezla · Otrexup · PENNSAID · Prolia · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI ARIA · SKYRIZI · STELARA · Strensiq · TALTZ · TREMFYA · Truxima · Tymlos · XELJANZ
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for a rheumatology specialist in Mesquite?
Compare rheumatologists in the Mesquite area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists in nearby ZIP areas
92
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
DALLAS REGIONAL MEDICAL CENTER
2.9 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Singhal is a mixed practice specialist, with above-average Medicare volume (top 19% in TX), with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Singhal experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Singhal performed 63,600 certolizumab injection (cimzia) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Singhal receive payments from pharmaceutical companies?
Yes. Dr. Singhal received a total of $39,065 from 39 companies across 997 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Singhal's costs compare to other rheumatologists in Mesquite?
Dr. Singhal's average Medicare payment per service is $4. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Singhal) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →